Yüksel Ürün· @DrYukselUrun · X·· 2 days agoScore90
Body
ctDNA is a risk signal, not yet a treatment compass?
KEYNOTE-B15: clearance 82.1% vs 66.7% with EV/pembro vs chemo. When can we safely act on it?
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @tompowles1 @urologysummit @isliquidbiopsy
487 views · 7 likes · 7 reposts · 0 replies
Conference abstracts
4734Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.orgNCT04700124NCT04700124matched by - **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.orgSource: Yüksel Ürün · x.com